Bluebird Bio is a biotechnology company focused on developing transformative gene therapies for severe genetic disorders and cancer
The company employs innovative genetic modification techniques to address the underlying causes of these diseases, aiming to provide long-lasting and potentially curative solutions for patients. With a commitment to advancing the field of gene therapy, Bluebird Bio is engaged in multiple clinical and preclinical programs that leverage its proprietary technology platform to deliver groundbreaking treatments, paving the way for the future of personalized medicine.
CMS launches an outcomes-based model to expand access to FDA-approved gene therapies for sickle cell disease, aiming to improve health outcomes and lower costs.
The FDA is investigating reports of life-threatening blood cancers linked to Skysona, a gene therapy for CALD. Providers are urged to consider safer alternatives and monitor patients for malignancies.
Bluebird Bio's Q3 earnings report showed a narrower-than-expected EPS loss but missed sales targets, leading to a JP Morgan downgrade and cash concerns.
A recent report reveals an increase in cancer cases among children treated with Bluebird Bio's Skysona gene therapy, raising concerns about the therapy's safety. Seven children in clinical trials have developed blood cancers, with one tragic death reported.
Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The initiative includes a 25% workforce reduction and focuses on advancing key gene therapy launches like LYFGENIA, ZYNTEGLO, and SKYSONA.
